Literature DB >> 23521519

EGFR and MYC gene copy number aberrations are more common in squamous cell carcinoma than keratoacanthoma: a FISH study.

Melissa S Jacobs1, Diane L Persons, Garth R Fraga.   

Abstract

Epidermal growth factor receptor (EGFR) and MYC genomic aberrations have been described in cutaneous squamous cell carcinoma (SCC) but have not been widely investigated in keratoacanthoma (KA). EGFR and MYC were evaluated by fluorescence in situ hybridization and immunohistochemistry in 8 verrucae, 19 involuting KA (IKA), 23 classic KA (CKA), 6 atypical KA (AKA) and 19 SCC. Increased EGFR gene copy number was seen in 9 of 23 CKA and 14 of 19 SCC (p = 0.03). Increased MYC gene copy number was observed in 7 of 23 CKA and 17 of 19 SCC (p = 0.0001). MYC gene amplification was more common in SCC than CKA (p = 0.005), while EGFR gene amplification was rare and not significant. MYC protein overexpression was identified in 6 of 23 CKA and 14 of 19 SCC (p = 0.005). There was no statistical difference in EGFR protein overexpression in SCC and CKA (p = 0.06). EGFR and MYC aberrations were rare in IKA. AKA showed EGFR and MYC anomalies at an incidence intermediate between CKA and SCC. EGFR and MYC gene copy number aberrations are more common in SCC than KA. The incidence of aberrations parallels the degree of cytologic atypia in KA.
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23521519     DOI: 10.1111/cup.12117

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  9 in total

1.  Keratoacanthoma and squamous cell carcinoma are distinct from a molecular perspective.

Authors:  Seong H Ra; Albert Su; Xinmin Li; Jaime Zhou; Alistair J Cochran; Rajan P Kulkarni; Scott W Binder
Journal:  Mod Pathol       Date:  2015-02-13       Impact factor: 7.842

2.  Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases.

Authors:  William L Read; Kevin T Brumund; Robert A Weisman; Angel Q Nguyen
Journal:  JAAD Case Rep       Date:  2015-05-25

3.  Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas.

Authors:  Doris Helbig; Alexander Quaas; Cornelia Mauch; Sabine Merkelbach-Bruse; Reinhard Büttner; Michael Emberger; Marion Wobser; Vanessa Rüsseler; Katharina Pütz; Elke Binot; Jan Rehker; Jan Budczies; Michaela Angelika Ihle
Journal:  Oncotarget       Date:  2017-11-25

4.  Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.

Authors:  Lydia A Hepburn; Angela McHugh; Kenneth Fernandes; Garry Boag; Charlotte M Proby; Irene M Leigh; Mark K Saville
Journal:  Oncotarget       Date:  2018-05-01

5.  Computer Image Analysis Reveals C-Myc as a Potential Biomarker for Discriminating between Keratoacanthoma and Cutaneous Squamous Cell Carcinoma.

Authors:  Xinyun Fan; Xueli Niu; Ze Wu; Lu Yao; Shirui Chen; Wenyu Wan; Bo Huang; Rui-Qun Qi; Tao Zhang
Journal:  Biomed Res Int       Date:  2022-08-23       Impact factor: 3.246

6.  Anti-cancer Therapies in High Grade Gliomas.

Authors:  Cristiana Pistol Tanase; Ana-Maria Enciu; Simona Mihai; Ana Iulia Neagu; Bogdan Calenic; Maria Linda Cruceru
Journal:  Curr Proteomics       Date:  2013-09       Impact factor: 0.837

7.  PKK suppresses tumor growth and is decreased in squamous cell carcinoma of the skin.

Authors:  Brian Poligone; Elaine S Gilmore; Carolina V Alexander; David Oleksyn; Kathleen Gillespie; Jiyong Zhao; Sherrif F Ibrahim; Alice P Pentland; Marc D Brown; Luojing Chen
Journal:  J Invest Dermatol       Date:  2014-10-06       Impact factor: 8.551

8.  Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.

Authors:  Angela McHugh; Kenneth Fernandes; Andrew P South; Jemima E Mellerio; Julio C Salas-Alanís; Charlotte M Proby; Irene M Leigh; Mark K Saville
Journal:  Oncotarget       Date:  2018-04-17

9.  Keratoacanthoma of the Lip: Activation of the mTOR Pathway, Tumor Suppressor Proteins, and Tumor Senescence.

Authors:  Caroline Siviero Dillenburg; Manoela Domingues Martins; Luise Meurer; Rogerio Moraes Castilho; Cristiane Helena Squarize
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.